Disease	Component of System	Definition		
Hepatitis A	HAV	Hepatitis A virus. Etiologic agent of infectious hepatitis. A picornavirus, the p type of a new genus, Hepatovirus.		
	Anti-HAV	Antibody to HAV. Detectable at onset of symptoms; lifetime persistence.		
	IgM anti-HAV	IgM class antibody to HAV. Indicates recent infection with hepatitis A; positive to 4–6 months after infection.		
Hepatitis B	HBV	Hepatitis B virus. Etiologic agent of serum hepatitis (long-incubation hepatitis) hepadnavirus.		
	HBsAg	Hepatitis B surface antigen. Surface antigen(s) of HBV detectable in large quant in serum; several subtypes identified.		
	HBeAg	Hepatitis B e antigen. Soluble antigen; associated with HBV replication, with high titers of HBV in serum, and with infectivity of serum.		
	HBcAg	Hepatitis B core antigen.		
	Anti-HBs	Antibody to HBsAg. Indicates past infection with and immunity to HBV, presence of passive antibody from HBiG, or immune response from HBV vaccine.		
	Anti-HBe	Antibody to HBeAg. Presence in serum of HBsAg carrier suggests lower titer of HBV.		
	Anti-HBc	Antibody to HBcAg. Indicates infection with HBV at some undefined time in the past.		
	IgM anti-HBc	IgM class antibody to HBcAg. Indicates recent infection with HBV; positive for 4–6 months after infection.		
Hepatitis C	HCV	Hepatitis C virus, a common etiologic agent of posttransfusion hepatitis. A fla- vivirus.		
	Anti-HCV	Antibody to HCV.		
Hepatitis D	HDV	Hepatitis D virus. Etiologic agent of delta hepatitis; causes infection only in presence of HBV.		
	HDAg	Delta antigen (delta-Ag). Detectable in early acute HDV infection.		
	Anti-HDV	Antibody to delta-Ag (anti-delta). Indicates past or present infection with HDV.		
Hepatitis E	HEV	Hepatitis E virus. Enterically transmitted hepatitis virus. Causes large epidemics in Asia and North Africa; fecal-oral or waterborne transmission. Perhaps a calicivirus.		
Immune globulins	IG	Immune globulin USP. Contains antibodies to HAV; no antibodies to HBsAg, HCV, or HIV.		
	HBIG	Hepatitis B immune globulin, Contains high titers of antibodies to HBV.		

30a

BOX 62-3 Unique Features of Hepadnaviruses

Virus has enveloped virion containing partially double-stranded, circular DNA genome.

Replication is through a circular RNA intermediate.

Virus encodes and carries a reverse transcriptase.

Virus encodes several proteins (HBsAg [L, M, S],


HBe/HBc) that share genetic sequences but with different in-frame start codons (AUG).

HBV has a strict tissue tropism to the liver.


HBV-infected cells produce and release large amounts of HBsAg particles lacking DNA.

The HBV genome can integrate into the host chromosome.


30b




30c




30d





30f







FIGURE 62-7 Major determinants of acute and chronic HBV infection.

HBV infects the liver but does not cause direct cytopathology. Cellmediated immune lysis of infected cells, potentially triggered by
interferon action, produces the symptoms and resolves the infection.

Insufficient immunity can lead to chronic disease. Chronic HBV disease
predisposes a person to more serious outcomes. Purple arrows indicate symptoms; green arrows indicate a possible outcome.

30h



Hepatitis B Serology						
	Anti-HBs	HBsAg	Anti-HBc IgM	Anti-HBc IgG	HBcAg	HBeAb
Acute hepatitis B		+	+	+	+	
Hepatitis B carrier	in agreement	+	_	+	<u></u>	+
Post hepatitis B infection	+		-	. +	-	***
Hepatitis B vaccination	+		- -	-	in the second second	

30j

Table 35-7. Transmission of hepatitis B virus and spectrum of outcomes to infection. Transmission Vertical (Asia) Contact (Africa) Parenteral, Sexual					
Age at infection	Newborns, infants	Young children	Teenagers, adults		
Recovery from acute infection	5%	20%	90-95%		
Progression to chronic infection	95%	80%	5-10%		
Chronic carriers ² (% of total population)	10-20%	10-20%	0.5%		

¹Vertical and contact-associated transmission occurs in endemic countries; parenteral and sexual transmission are main modes in nonendemic countries.

²At high risk of developing hepatocellular carcinoma.

30k

